The filing content is substantial enough to proceed, but it cuts off mid-sentence. I'll work with what's available.

Seres Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing going concern doubt and an ongoing need for additional funding.

Key Highlights

  • Going concern doubt: The company disclosed "conditions and events that raise substantial doubt regarding our ability to continue as a going concern."
  • Additional funding required: According to the filing, the company will need additional funding to advance development of SER-155 and other product candidates, and to commercialize them if approved.
  • Bankruptcy risk noted: The filing states that if the company is unable to raise capital or secure a partnership, it could pursue alternatives "which could include seeking relief under the U.S. Bankruptcy Code or winding down our operations."
  • Shares outstanding: As of November 2, 2026, the registrant had 10,195,031 shares of common stock, $0.001 par value per share, outstanding.
  • Smaller reporting company: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Clinical-stage operations: The filing states the company "has incurred significant losses since our inception" and expects "to incur losses for the foreseeable future and may never achieve or maintain profitability."

Seres Therapeutics Flags Funding Gap and Potential Wind-Down in Q3 2026 Report

Seres Therapeutics, Inc. (NASDAQ:MCRB), a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing identifies going concern doubt as a principal risk, stating that conditions and events have been identified that raise substantial doubt about the company's ability to continue as a going concern.

According to the filing, the company requires additional capital to advance its product candidates, including to conduct a Phase 2 study of SER-155 in allo-HCT and a potential next study of SER-155 in irEC, as well as to advance earlier-stage programs. The filing discloses that if the company is unable to raise capital or secure a partnership or other business development transaction, it could be required to "implement further cost-reduction measures, reduce or delay our product development programs or potential future commercialization efforts, or pursue other alternatives, which could include seeking relief under the U.S. Bankruptcy Code or winding down our operations."

The filing also notes that the company's "limited operating history may make it difficult to evaluate the success of our business to date and to assess our future viability." As of November 2, 2026, the company reported 10,195,031 shares of common stock outstanding at a par value of $0.001 per share. The report contains forward-looking statements, which the company has identified as subject to material risks, uncertainties, and cautionary factors described in the Risk Factors and Management's Discussion and Analysis sections of the filing.

What Was Disclosed

Seres Therapeutics filed a Form 10-Q for Q3 2026, disclosing substantial doubt about its ability to continue as a going concern, a requirement for additional capital, and the possibility of bankruptcy or wind-down if funding cannot be secured.